###begin article-title 0
Heparanase Facilitates Cell Adhesion and Spreading by Clustering of Cell Surface Heparan Sulfate Proteoglycans
###end article-title 0
###begin p 1
Conceived and designed the experiments: IV NI FL SF ES. Performed the experiments: FL SF ES. Analyzed the data: IV NI FL SF ES. Wrote the paper: IV NI FL.
###end p 1
###begin p 2
###xml 559 562 559 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">158</sup>
###xml 566 569 566 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">171</sup>
Heparanase is a heparan sulfate (HS) degrading endoglycosidase participating in extracellular matrix degradation and remodeling. Apart of its well characterized enzymatic activity, heparanase was noted to exert also enzymatic-independent functions. Non-enzymatic activities of heparanase include enhanced adhesion of tumor-derived cells and primary T-cells. Attempting to identify functional domains of heparanase that would serve as targets for drug development, we have identified heparin binding domains of heparanase. A corresponding peptide (residues Lys158-Asp171, termed KKDC) was demonstrated to physically associate with heparin and HS, and to inhibit heparanase enzymatic activity. We hypothesized that the pro-adhesive properties of heparanase are mediated by its interaction with cell surface HS proteoglycans, and utilized the KKDC peptide to examine this possibility. We provide evidence that the KKDC peptide interacts with cell membrane HS, resulting in clustering of syndecan-1 and syndecan-4. We applied classical analysis of cell morphology, fluorescent and time-lapse microscopy and demonstrated that the KKDC peptide efficiently stimulates the adhesion and spreading of various cell types, mediated by PKC, Src, and the small GTPase Rac1. These results support, and further substantiate the notion that heparanase function is not limited to its enzymatic activity.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 158 161 158 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Selleck1">[1]</xref>
###xml 590 593 590 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Selleck1">[1]</xref>
###xml 1012 1015 1012 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Kjellen1">[2]</xref>
###xml 1017 1020 1017 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Jackson1">[3]</xref>
###xml 1249 1252 1249 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sasisekharan1">[4]</xref>
###xml 1509 1512 1509 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Bernfield1">[5]</xref>
###xml 1513 1516 1513 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Timpl1">[7]</xref>
###xml 1710 1713 1710 1713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Selleck1">[1]</xref>
###xml 1715 1718 1715 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sasisekharan1">[4]</xref>
###xml 1720 1723 1720 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Capila1">[8]</xref>
###xml 1725 1728 1725 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Cardin1">[9]</xref>
###xml 1863 1867 1863 1867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Belting1">[10]</xref>
###xml 1950 1954 1950 1954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Belting1">[10]</xref>
###xml 2035 2039 2035 2039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky1">[11]</xref>
###xml 2040 2044 2040 2044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky3">[15]</xref>
###xml 2290 2294 2290 2294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-PageMcCaw1">[16]</xref>
###xml 2296 2300 2296 2300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Werb1">[17]</xref>
Proteoglycans are proteins that bear long, un-branched sugar polymers, glycosaminoglycans, which are attached to specific serine residues of the protein core [1]. Glycosaminoglycans are polymers of disaccharide units. In the case of heparan sulfate, uronic acid (either glucuronic acid or iduronic acid) and N-acetyl glucosamine repeats compose the basic structure of the proteoglycan. Despite the seemingly simple, single repeating structural motif, these sugar polymers show a great deal of structural diversity generated by complex pattern of deacetylation, sulfation, and epimerization [1]. Thus, a single heparan sulfate proteoglycan (HSPG) side chain contains distinct structural domains, composed of regions of highly sulfated, negatively-charged residues alongside of regions with modest levels of sugar modifications. Proteoglycans are abundant components of the basement membrane and extracellular matrix (ECM) of epithelium, endothelium, and connective tissues including cartilage, tendons, and bones [2], [3]. In addition, proteoglycans are also abundantly present on the cell surface, providing an important constituent of the cell's sugar coat involved in various aspects of cellular and molecular activities at the cell-ECM interface [4]. By interacting with other macromolecules such as laminin, fibronectin, and collagens I and IV, HSPGs contribute to the structural integrity, self-assembly and insolubility of the ECM and basement membrane, thus intimately modulating cell-ECM interactions [5]-[7]. ECM constituents are, however, only one class of HS-binding molecules. In fact, numerous enzymes, growth factors, cytokines and chemokines are sequestered by HSPGs on the cell surface and ECM [1], [4], [8], [9]. In general, HSPGs facilitate the biological activity of bound ligands by actively participating in receptor-ligand complex formation [10]. In other cases, HSPGs mediate cellular uptake and catabolism of selected ligands [10], or sequester polypeptides to the ECM and cell surface as an inactive reservoir [11]-[15]. Cleavage of HSPGs would ultimately release these proteins and convert them into bioactive mediators, ensuring rapid tissue response to local or systemic cues. The protein core of HSPGs is susceptible to cleavage by several classes of proteases [16], [17]. An additional mode of HSPGs cleavage is offered by the enzyme heparanase.
###end p 4
###begin p 5
###xml 106 110 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-McKenzie1">[18]</xref>
###xml 437 441 434 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-BarNer1">[19]</xref>
###xml 442 446 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky4">[21]</xref>
###xml 578 582 575 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-McKenzie1">[18]</xref>
###xml 584 588 581 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Ilan1">[22]</xref>
###xml 589 593 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky5">[25]</xref>
###xml 841 845 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Ilan1">[22]</xref>
###xml 847 851 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky5">[25]</xref>
###xml 1093 1097 1090 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
###xml 1108 1112 1105 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Goldshmidt1">[27]</xref>
###xml 1125 1129 1122 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sotnikov1">[28]</xref>
###xml 1207 1211 1201 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
###xml 1213 1217 1207 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sotnikov1">[28]</xref>
###xml 530 535 <span type="species:ncbi:9606">human</span>
Heparanase is an endo-beta-glucuronidase that cleaves HS side chains presumably at sites of low sulfation [18], releasing saccharide products with appreciable size (5-7 kDa) that can still associate with protein ligands and modulate their biological potency. Heparanase activity has been traditionally correlated with cell invasion associated with cancer metastasis, a consequence of structural modification that loosens the ECM barrier [19]-[21]. More recently, heparanase up-regulation was documented in an increasing number of human carcinomas and hematological malignancies [18], [22]-[25]. In many cases, heparanase induction correlated with increased tumor metastasis, vascular density, and shorter post operative survival rate, thus providing a strong clinical support for the pro-metastatic and pro-angiogenic function of the enzyme [22], [25]. In addition to the well studied catalytic feature of the enzyme, heparanase was noted to exert biological functions apparently independent of its enzymatic activity. Non enzymatic functions of heparanase include enhanced adhesion of glioma [26], lymphoma [27] and T cells [28], mediated by beta1-integrin and correlated with Akt, Pyk2 and ERK activation [26], [28].
###end p 5
###begin p 6
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 202 205 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">158</sup>
###xml 209 212 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">171</sup>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
Attempting to identify functional domains that would serve as a target for drug development, we have recently identified heparin binding domains of heparanase [29]. A corresponding peptide (residues Lys158-Asp171, termed KKDC) was demonstrated to physically associate with heparin and HS, and to inhibit heparanase enzymatic activity [29]. We hypothesized that the pro-adhesive properties of heparanase are mediated by its interaction with cell surface HSPGs and utilized the unique feature of the KKDC peptide to examine this possibility.
###end p 6
###begin p 7
###xml 336 340 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Beauvais1">[30]</xref>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Couchman1">[31]</xref>
###xml 692 696 692 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Beauvais1">[30]</xref>
###xml 697 701 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Saoncella1">[32]</xref>
###xml 967 971 963 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Tkachenko1">[33]</xref>
###xml 973 977 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Woods1">[34]</xref>
###xml 1453 1457 1445 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Tkachenko1">[33]</xref>
###xml 1458 1462 1450 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Tkachenko2">[37]</xref>
Syndecans are a family of four transmembrane proteins capable of carrying chondroitin sulfate (CS) and HS chains. Syndecans are expressed on virtually all cell types throughout development and adulthood, and their expression can be altered under certain pathophysiological conditions, including tumor onset, progression, and metastasis [30], [31]. The presence of HS chains allows interactions with a large number of proteins, including heparin-binding growth factors, plasma proteins such as antithrombin, and extracellular matrix proteins including fibronectin. In addition, syndecans are thought to function as co-receptors, facilitating growth factors, morphogens, and integrins activity [30]-[32]. Furthermore, syndecans can associate with a large number of adaptor and signaling molecules through their cytolplasmic tail, despite being relatively small. These include ezrin, tubulin, cortactin, PDZ domain-containing proteins (i.e., syntenin), Src and PKCalpha [33], [34]. Syndecans emerge as central players in the interactions between the ECM and the cell surface that ultimately regulate cell spreading, adhesion, and migration. This function was largely attributed to a direct interaction of syndecans with matrix proteins such as fibronectin. In addition, clustering of syndecan-4 has been shown to initiate signaling cascades that results in PKCalpha and Rac1 activation that appears instrumental for cell adhesion and directional migration [33]-[37].
###end p 7
###begin p 8
Here, we provide evidence that the KKDC peptide interacts with plasma membrane HS, and facilitates clustering of syndecan-1 and syndecan-4. Interestingly, while the heparanase-syndecan complex is subjected to rapid internalization and appears in endocytic vesicles short after the addition of heparanase, the KKDC peptide elicits syndecan clusters that remain on the cell surface for a relatively long period of time and fail to get internalized. We demonstrate that the KKDC peptide efficiently stimulates the adhesion and spreading of multiple cell types by activating the PKC pathway and the small GTPase Rac1. These results support and further expand the notion that heparanase function is not limited to its enzymatic activity, and highlight heparin binding domains as targets for the development of anti-cancer inhibitors.
###end p 8
###begin title 9
Materials and Methods
###end title 9
###begin title 10
Antibodies and reagents
###end title 10
###begin p 11
###xml 957 961 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 1236 1237 1236 1237 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</underline>
###xml 1236 1237 1236 1237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>K</underline></bold>
###xml 1237 1243 1237 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">biotin</sup>
###xml 1375 1379 1375 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 1479 1483 1479 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Woods2">[38]</xref>
Anti syndecan-1 monoclonal antibody (B-B4) was purchased from Serotec (Oxford, UK). Antibodies to syndecan-4 and paxillin were purchased from Santa Cruz Biotechnology (Sanata Cruz, CA). Anti-Rac 1 monoclonal antibody was purchased from Becton Dickinson Biosciences (San Diego, CA), and PAK PBD-agarose beads were from Cell Biolabs Inc (San Diego, CA). Anti-vinculin monoclonal antibody, phalloidin-TRITC, heparin, fibronectin, and the 110 kDa fibronectin-like genetically engineered protein, were purchased from Sigma (St. Louis, MO). Avidin-FITC was purchased from Vector (Burlingame, CA). The selective p38 (SB-203580), Src (PP2), Erk (PD-98059), PKC [Bisindolylmaleimide I (Bis)], Rock (Y27632) and Rac (NSC 23766) inhibitors were purchased from Calbiochem (San Diego, CA) and were dissolved in DMSO as stock solutions. DMSO was added to the cell culture as a control. The KKDC and its control, scrambled peptide were synthesized as described previously [29]. The introduced C-terminal cysteine residue mediates spontaneous peptide dimerization that can be further facilitated by enhanced oxygenation generated by stirring. For biotin labeling, an extra lysine residue was introduced at position 12 to create the sequence KKFKNSTYSRSKbiotinSVDC. This approach was undertaken in order to preserve the N-terminal lysine residues critical for the peptide interaction with HS [29]. A peptide from the COOH-terminal heparin-binding domain of fibronectin (Hep II peptide, WQPPRARI) [38] was purchased from Sigma (St. Louis, MI).
###end p 11
###begin title 12
Cells and cell culture
###end title 12
###begin p 13
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-GingisVelitski1">[39]</xref>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Nadav1">[40]</xref>
###xml 786 787 786 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1109 1113 1103 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-GingisVelitski1">[39]</xref>
###xml 1275 1279 1269 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Hulett1">[41]</xref>
###xml 1377 1381 1371 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser2">[42]</xref>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 24 28 <span type="species:ncbi:307630">Colo</span>
###xml 120 123 <span type="species:ncbi:10116">Rat</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 732 736 <span type="species:ncbi:9913">calf</span>
###xml 813 828 <span type="species:ncbi:10029">Chinese hamster</span>
U87 MG human glioma and Colo 320 colon carcinoma cells were purchased from the American Type Culture Collection (ATCC). Rat C6 glioma cells were kindly provided by Dr. Eli Keshet (The Hebrew University Hadassah Medical School, Jerusalem) [39], and human skin fibroblasts were kindly provided by Dr. H. Mendel (Rambam Health Care Campus, Haifa). ARH-77 leukemia-derived F cells were kindly provided by Dr. Ben-Zion Katz (Soraski Medical Center, Tel-Aviv, Israel). F cells are a sub-population of the ARH-77 cell line which poorly adhere and mainly floats (F) once plated on fibronectin-coated dishes [40]. Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with glutamine, pyruvate, antibiotics and 10% fetal calf serum in a humidified atmosphere containing 5% CO2 at 37degreesC. Wild type Chinese hamster ovary (CHO) K1 and mutant cells (pgs A-745) deficient in xylosyltransferase and unable to initiate glycosaminoglycan synthesis, were kindly provided by Dr. Jeffery Esko (University of California, San Diego), and grown in RPMI 1640 medium supplemented with 10% FCS and antibiotics [39]. Recombinant wild type and enzymatically-inactive heparanase mutated at glutamic acid residues 225 and 343 [double mutant (DM)] critical for enzymatic catalysis [41] were purified from the conditioned medium of HEK 293 transfected cells, essentially as described [42].
###end p 13
###begin title 14
Cell morphology and immunocytochemistry
###end title 14
###begin p 15
###xml 1216 1220 1208 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Shafat1">[43]</xref>
###xml 1222 1226 1214 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser3">[44]</xref>
###xml 584 588 <span type="species:ncbi:9925">goat</span>
Cells were plated on glass cover slips uncoated or coated with fibronectin or the 110 kDa fibronectin-like protein for the time indicated in the absence (Con) or presence of the indicated peptides [scrambled (Scr), or KKDC; (50 microg/ml)], proteins [latent 65 kDa or mutated, enzymatically inactive heparanase (1 microg/ml)], or inhibitors. Cells were then fixed with 4% paraformaldehyde in PBS for 15 minutes, and visualized. For immunofluorescent staining, cells were fixed with cold methanol for 10 minutes, washed with PBS and subsequently incubated in PBS containing 10% normal goat serum for 1 hour at room temperature, followed by 2 hours incubation with the indicated primary antibody. Cells were then extensively washed with PBS and incubated with the relevant Cy2/Cy3-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA) for 1 hour, washed and mounted (Vectashield, Vector, Burlingame, CA). Staining was observed under a fluorescent confocal microscope. For actin staining, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% triton X-100 for 2 minutes, washed and incubated with TRITC-phalloidin (Sigma) for 30 minutes and visualized by confocal microscopy, as described [43], [44].
###end p 15
###begin title 16
Cell lysates and protein blotting
###end title 16
###begin p 17
###xml 648 652 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 654 658 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam2">[45]</xref>
###xml 1101 1105 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
Cell cultures were incubated for 24 hours under serum-free conditions, pretreated with 1 mM orthovanadate for 10 minutes at 37degreesC, washed twice with ice cold PBS containing 1 mM orthovanadate and scraped into lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton-X100, 1 mM orththovanadate, 1 mM PMSF) containing a cocktail of protease inhibitors (Roche, Mannheim, Germany). Total cellular protein concentration was determined by the BCA assay, according to the manufacturer's (Pierce, Rockford, IL) instructions. Thirty micrograms of cellular protein were subjected to SDS polyacrylamid gel (SDS-PAGE) and immunoblotting, as described [29], [45]. For estimation of Rac1 activation, lysis buffer included 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10 mM MgCl, 4% glycerol, and 1% Triton X-100. The amount of GTP-bound Rac1 was analyzed by incubating total cell lysates (200 microg) with 20 microg of the p21-binding domain (PBD) of PAK-agarose beads. Following 30 minutes incubation, the beads were washed and, after electrophoresis and blotting, membranes were probed with anti-Rac1 antibodies [26].
###end p 17
###begin title 18
Time Lapse microscopy
###end title 18
###begin p 19
Cells were grown on Corning/Nunc 6 wells dishes in DMEM medium and viewed with inverted motorized microscope (DMIRE2 Leica, Germany). Images were captured using cooled B/W CCD camera (Retiga EXI, Qimaging, USA). Time-lapse acquisition was made with custom written software (Provided by Uri Alon, Weizmann Institute, Rehovot, Israel), inserted into Image-Pro software (MediaCybernetics, USA). The system is equipped with an on stage incubator (Cube & Box, LIS, Switzerland).
###end p 19
###begin title 20
Results
###end title 20
###begin title 21
The KKDC peptide interacts with the plasma membrane
###end title 21
###begin p 22
###xml 160 163 160 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">158</sup>
###xml 167 170 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">171</sup>
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 594 598 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 742 749 742 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1A</xref>
###xml 841 848 841 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1A</xref>
###xml 915 922 915 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1A</xref>
###xml 1061 1068 1061 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1A</xref>
###xml 1319 1326 1319 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1B</xref>
###xml 1592 1596 1592 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vreys1">[46]</xref>
We have identified heparin binding domains that mediate the interaction of heparanase with its HS substrate and demonstrated that a peptide corresponding to Lys158-Asn171 (KKDC), inhibits heparanase enzymatic activity [29]. Although the KKDC peptide has been shown to physically interact with heparin and HS [29], binding and localization at the cellular level have not been so far demonstrated. For this purpose, the KKDC and control, scrambled peptides were labeled with biotin on an extra lysine residue introduced in order to maintain the N-terminal lysine residues critical for HS binding [29] intact, and peptide binding was detected by Avidin-FITC. No detectable binding of the control, scrambled peptide to CHO K1 cells was observed (Fig. 1A, Scr). In contrast, the KKDC peptide gave rise to a punctuated, readily detected staining (Fig. 1A, KKDC) that was significantly reduced by the addition of heparin (Fig. 1A, KKDC+heparin). Furthermore, no staining was detected upon addition of the biotinylated KKDC peptide to CHO-745 cells deficient of HSPGs (Fig. 1A, KKDC/745), suggesting that the KKDC peptide interacts with cell surface HSPGs. Interaction of the KKDC peptide with cell membrane molecules, lack of interaction with CHO-745 cells, and heparin competition were further demonstrated by FACS analysis (Fig. 1B). Thus, the KKDC peptide enables to elucidate the effect of heparanase-HS interaction on cell behavior, excluding other classes of heparanase binding proteins such as low density lipoprotein receptor-related protein (LRP) and the mannose 6-phosphate receptor (MPR) [46].
###end p 22
###begin title 23
The KKDC peptide interacts with plasma membrane heparan sulfate.
###end title 23
###begin p 24
A,B: peptide binding. Wild type (CHO K1; a-c) and heparan sulfate-deficient (CHO-745; d) cells were incubated (2 hours) with biotinylated KKDC (b-d) or control peptide (Scr; a) in the absence (a, b, d) or presence (c) of 10 microg/ml heparin. Cells were then washed, fixated with 4 % paraformaldehyde and bound peptide was visualized with avidin-FITC and fluorescence microscopy (A) or analyzed by FACS Scan (B). C, D Heparanase and the KKDC peptide promotes cell adhesion. Leukemia-derived ARH-77 cells that were selected to grow in suspension (F cells), were plated on fibronectin coated plates for 30 minutes in the presence of heparanase (Hepa; 1 microg/ml), inactive heparanase (DM; 1 microg/ml), KKDC peptide (50 microM), or control peptide (Scr, 50 microM). Plates were gently washed and cell adhesion was visualized by light microscopy (C). Adherent cells were counted and quantified (D).
###end p 24
###begin title 25
Inactive heparanase facilitates leukemia cell adhesion
###end title 25
###begin p 26
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Goldshmidt1">[27]</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Nadav1">[40]</xref>
###xml 585 594 585 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1C&amp;D</xref>
###xml 768 777 768 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1C&amp;D</xref>
###xml 878 882 878 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Goldshmidt1">[27]</xref>
###xml 906 912 906 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1</xref>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
We have previously noted that over expression of heparanase enhances the adhesion of mouse Eb lymphoma cells to ECM and endothelial cells. Augmented cell adhesion was maintained by cells transfected with point mutated, inactive heparanase, or in the presence of laminaran sulfate, an inhibitor of heparanase enzymatic activity [27], arguing for enzymatic-independent function. Similarly, exogenous addition of purified latent 65 kDa heparanase to poorly adhesive human leukemia ARH-77 F cells, selected to grow in suspension [40], significantly enhanced their adhesion to fibronectin (Fig. 1C&D, Hepa). Moreover, addition of recombinant, enzymatically inactive double mutated (DM) heparanase facilitated F cells adhesion similar in magnitude to the wild type protein (Fig. 1C&D, DM), further supporting the notion that improved cellular adhesion upon heparanase over-expression [27] or exogenous addition (Fig. 1) does not involve enzymatic aspects.
###end p 26
###begin p 27
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser2">[42]</xref>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Nadir1">[47]</xref>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sotnikov1">[28]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Beauvais1">[30]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Couchman1">[31]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Woods1">[34]</xref>
###xml 751 760 751 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1C&amp;D</xref>
###xml 826 833 826 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1C</xref>
The scope of heparanase function has recently been challenged by evidence documenting its ability to activate signaling molecules (i.e., Akt, p38, Src) in an enzymatic-independent manner, resulting in enhanced gene transcription [42], [47] and cell adhesion [26]-[28]. Enhanced cell adhesion by heparanase may be due to binding and activation of plasma membrane proteins such as syndecans, a class of trans-membrane HSPGs shown to modulate adhesion complexes [30], [31], [34]. In order to examine this possibility, we took advantage of the specific feature of the KKDC peptide and exposed ARF-77 F cells to the KKDC peptide or its control, scrambled counterpart. Indeed, the KKDC peptide elicited a significant, two-fold increase in F cells adhesion (Fig. 1C&D, KKDC), while the control, scrambled peptide had no such effect (Fig. 1C, Scr). These results suggest that interaction between heparanase and plasma membrane HSPGs is sufficient to enhance cell adhesion.
###end p 27
###begin title 28
The KKDC peptide induces syndecan clustering and enhances cell spreading
###end title 28
###begin p 29
###xml 80 86 80 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 218 224 218 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-GingisVelitski1">[39]</xref>
###xml 428 434 428 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 506 512 506 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 839 845 835 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 1014 1020 1006 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
Syndecan-4 appears regularly spread in the plasma membrane of U87 glioma cells (Fig. 2, upper panels, Scr). In contrast, syndecan-4 was mostly localized to perinuclear endocytic vesicles following heparanase addition (Fig. 2, upper panels, Hepa), co-localizing with heparanase [39]. Interestingly, however, syndecan-4 was not internalized upon the addition of the KKDC peptide but rather appeared clustered on the cell surface (Fig. 2, upper panels, KKDC). A similar localization was noted for syndecan-1 (Fig. 2, middle panel, KKDC). Next, we examined U87 cell spreading upon stimulation with heparanase or the KKDC peptide by staining the cells for paxillin, a well-characterized focal-adhesion component. Cells treated with heparanase (1 microg/ml) appeared better spread and focal adhesion complexes were nicely decorated by paxillin (Fig. 2, lower panels, Hepa, arrows). Enhanced cell spreading was even more pronounced in the presence of the KKDC peptide (50 microM), where multiple focal contacts appeared (Fig. 2, lower panels, KKDC), indicating that syndecans clustering by the KKDC peptide facilitates cellular spreading. These observations were further confirmed by employing several additional cell adhesion systems.
###end p 29
###begin title 30
The KKDC peptide induces syndecan clustering and enhances cell spreading.
###end title 30
###begin p 31
U87 cells were serum starved for 24 hours and were then incubated with the KKDC/Scr peptides (50 microM) or heparanase (1 microg/ml) for 1 hour. Cells were then gently washed, fixed with cold methanol and subjected to fluorescent staining with anti-syndecan-4 (upper panels) or anti-syndecan-1 (middle panels) antibodies. U87 cells were also plated on the 110 kDa fibronectin-like protein and incubated for 4 hours in the presence of KKDC/Scr peptides (50 microM) or heparanase (1 microg/ml). Cells were then washed, fixed with 4% paraformaldehyde and stained with anti-paxillin antibodies (lower panels).
###end p 31
###begin p 32
###xml 234 241 234 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3A</xref>
###xml 248 256 248 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s001">Movie S1</xref>
###xml 348 355 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3A</xref>
###xml 363 371 363 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s002">Movie S2</xref>
###xml 408 415 408 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3A</xref>
###xml 423 431 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s003">Movie S3</xref>
###xml 486 493 486 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3A</xref>
###xml 509 517 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s004">Movie S4</xref>
###xml 622 629 622 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3B</xref>
###xml 697 704 697 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3B</xref>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 544 548 <span type="species:ncbi:307630">Colo</span>
Rat C6 glioma cells rapidly adhere and spread once plated on tissue culture plastic dish. The cells, however, assume a round morphology once cultured in serum-free medium, and remained round following the addition of control peptide (Fig. 3A, Scr; Movie S1). In striking contrast, cells appeared nicely spread following the addition of heparanase (Fig. 3A, Hepa; Movie S2) and even more so the KKDC peptide (Fig. 3A, KKDC; Movie S3), an effect that was completely inhibited by heparin (Fig. 3A, lower panels; Movie S4). Similarly, treatment of Colo 320 colon carcinoma cells with the KKDC peptide enhanced cell spreading (Fig. 3B, KKDC) and focal complexes formation evident by paxillin staining (Fig. 3B, KKDC, inset).
###end p 32
###begin title 33
The KKDC peptide induces cell spreading.
###end title 33
###begin p 34
A. C6 glioma cells were serum-starved for 24 hours, and were then incubated with heparanase (1 microg/ml), KKDC or control (Scr) peptides (50 microM) for 18 hours in the absence (upper panels) or presence of heparin (50 microg/ml; lower panels). Cell spreading was evaluated by light microscopy. B. Colo320 colon carcinoma cells were plated on fibronectin for 1 hour followed by incubation with the KKDC (lower panel) or the control (Scr; upper panel) peptides (50 microM) for additional 18 hours. Cell spreading was evaluated by light microscopy and by staining for paxillin (insets).
###end p 34
###begin p 35
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Hynes1">[48]</xref>
###xml 329 331 329 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Barkalow1">[49]</xref>
###xml 748 754 748 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 787 791 787 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Saoncella1">[32]</xref>
###xml 889 895 889 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 959 965 959 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 1065 1071 1065 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 1158 1164 1158 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 1435 1441 1435 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 1311 1316 <span type="species:ncbi:9606">human</span>
Fibronectin is a multifunctional glycoprotein that mediates a number of important biological functions including cell adhesion and migration [48]. The diverse biological activities attributed to fibronectin have been localized to specific molecular domains. Thus, the main cell binding, RGD-rich domain is localized within the 10th type III module, while heparin binding is mediated by modules 12-14 [49]. Fibronectin-like protein polymer has been engineered to include 13 copies of the RGD-rich sequence, resulting in a protein with a stable three-dimensional conformation and molecular mass of 110 kDa. CHO K1 cells plated on dishes coated with the 110 kDa fibronectin-like protein adhered, but failed to spread and appeared round in morphology (Fig. 4, Scr, upper panel), as expected [32]. In contrast, CHO K1 cells plated on the fibronectin-like protein in the presence of heparanase (Fig. 4, Hepa) or the KKDC peptide appeared elongated and more spread (Fig. 4, upper panels). In addition, cells treated with heparanase exhibited typical membrane protrusions (Fig. 4, inset), and actin stress fibers were evident in cells treated with the KKDC peptide (Fig. 4, inset). Similarly, enhanced stress fiber and focal complexes formation, evident by phalloidin and vinculin staining, respectively, were noted in human fibroblasts plated on the 110 kDa fibronectin-like polymer substrate and treated with heparanase or the KKDC peptide (Fig. 4, lower panels). Collectively, these results suggest that syndecan clustering by heparanase or the KKDC peptide facilitates cell adhesion and spreading and can substitute, to some extent, the heparin binding domains of fibronectin.
###end p 35
###begin title 36
Heparanase and the KKDC peptide enhance cell spreading and formation of actin stress fibers.
###end title 36
###begin p 37
###xml 20 25 <span type="species:ncbi:9606">human</span>
CHO cells (a-c) and human fibroblasts (d-f) were plated on the 110 kDa fibronectin-like protein and incubated with heparanase (Hepa; 1 microg/ml) or the KKDC/Scr peptides (50 microM) for 18 hours (a-c) or 1 hour (d-f). Cells were then visualized by light microscopy (a-c) or fixed with 4% paraformaldehyde and stained with phalloidin-TRITC (a-c, insets) or double stained with phalloidin-TRITC (red) and anti-vinculin (green) antibody (d-e). Cells treated with heparanase (b,e) or with the KKDC peptide (c,f) appeared spread and formed more focal adhesions (e,f).
###end p 37
###begin title 38
Enhanced cell spreading by heparanase/KKDC is mediated by PKC, Src, and Rac1
###end title 38
###begin p 39
###xml 127 133 127 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 328 334 328 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 356 362 356 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 579 585 579 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 687 693 687 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 710 716 710 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 770 776 770 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 882 888 882 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 906 911 906 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig 5</xref>
###xml 934 940 934 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g005">Fig. 5</xref>
###xml 1081 1085 1081 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Burridge1">[50]</xref>
###xml 1380 1384 1380 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Burridge1">[50]</xref>
###xml 1838 1845 1838 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g006">Fig. 6A</xref>
###xml 1976 1983 1976 1983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g006">Fig. 6A</xref>
###xml 2051 2058 2051 2058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g006">Fig. 6A</xref>
###xml 2196 2203 2196 2203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g006">Fig. 6B</xref>
###xml 2277 2284 2277 2284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g006">Fig. 6B</xref>
###xml 2445 2452 2445 2452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g006">Fig. 6C</xref>
###xml 2573 2577 2573 2577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-delPozo1">[51]</xref>
As shown above, CHO K1 cells depend on heparanase or the KKDC peptide for spreading on the 110 kDa fibronectin-like substrate (Fig. 4). We, next, utilized this cell system to examine signaling pathways that mediate the effect of heparanase. To this end, cells were plated on the 110 kDa fibronectin-like substrate without (Con, Fig. 5) or with heparanase (Fig. 5, Hepa), or pretreated with the indicated inhibitor prior to heparanase addition, and cell spreading was then examined. As previously noted, CHO K1 cells spreading was markedly enhanced in the presence of heparanase (Fig. 5, Hepa). Cell spreading stimulated by heparanase was not significantly altered by inhibitors of MAPK (Fig. 5, Hepa+PD), PKA (Fig. 5, Hepa+H89), or ROCK, a down stream effector of RhoA (Fig. 5, Hepa+Y27632). In contrast, cell spreading stimulated by heparanase was significantly attenuated by Src (Fig. 5, Hepa+PP2), PKC (Fig 5, Hepa+Bis), and Rac1 (Fig. 5, Hepa+NSC 23766) inhibitors. The small GTPase Rac1 is thought to play instrumental roles in the early phases of cell adhesion and spreading [50]. Thus, initial membrane protrusion is governed by Cdc42 and Rac1 activation, resulting in filopodia/lamellipodia extensions and focal complexes formation. Subsequent activation of RhoA induces the maturation of focal complexes to focal adhesions, assembly of stress fibers, and cell locomotion [50]. Given the observed enhancement of cell adhesion and spreading upon heparanase/KKDC treatment, we examined RhoA and Rac1 activation by employing agarose beads coupled to RhoA-binding domain of Rhotekin, and the p-21 binding domain (PBD) of p21-activated protein kinase (PAK) that specifically binds the active, GTP-bound form of RhoA and Rac1, respectively. Rac1 activation was markedly induced following heparanase addition to ARF-77 leukemia F cells (Fig. 6A, Hepa, upper panel). Double-mutated, inactive heparanase (DM) and the KKDC peptide stimulated Rac1 activation to the same extent (Fig. 6A, DM, upper panel) or even higher (KKDC) than wild type heparanase (Fig. 6A, upper panel). Similarly, a significant activation of Rac1 was noted in U87 glioma cells stimulated with heparanase or the KKDC peptide (Fig. 6B, upper panel), activation that was abolished by the addition of heparin (Fig. 6B+heparin), while RhoA activation was not evident (not shown). Moreover, Rac1 was noted to assume membrane localization following heparanase or KKDC stimulation (Fig. 6C), a cellular translocation that is considered essential for the activation of down stream effectors, and cell migration [51].
###end p 39
###begin title 40
Cell spreading induced by heparanase is mediated by PKC, Rac, and Src.
###end title 40
###begin p 41
CHO cells were plated on the 110 kDa fibronectin-like protein, without (Con) or with heparanase, in the absence (Hepa) or presence of selective PKC (Bis), Src (PP2), ROCK (Y27632), MAPK (PD), PKA (H89), and Rac (NSC 23766) inhibitors for 6 hours. Cells were then fixed with 4% paraformaldehyde and stained with phalloidin-TRITC.
###end p 41
###begin title 42
Heparanase and the KKDC peptide induce Rac1 activation.
###end title 42
###begin p 43
###xml 363 384 355 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 748 753 <span type="species:ncbi:9606">Human</span>
A. F cells were washed with serum free medium and were then treated for 30 minutes with the KKDC/Scr peptides (50 microM), wild type heparanase (Hepa) or inactive double mutant heparanase (DM) in serum free medium. Cell lysates (100 microg) were then subjected to pull-down with GST-PAK-agarose beads for detection of active Rac1 (upper panels), as described in "Materials and Methods". Cell lysates (30 microg) were subjected to immunoblotting with anti-Rac1 antibody (lower panels). B. U87 cells were kept in serum-free medium for 24 hours and were then stimulated with the KKDC/Scr peptides (50 microM) or heparanase (Hepa; 1 microg/ml) for 30 min without or with heparin (50 microg/ml; +heparin). Rac activation was then evaluated as above. C. Human umbilical vein endothelial cells (HUVEC) were plated on the 110 kDa fibronectin-like protein and were incubated with the KKDC/Scr peptides (50 microM) or heparanase (Hepa; 1 microg/ml) for 3 hours. Cells were then fixed and stained with anti-Rac1 antibody. Note Rac1 localization to the plasma membrane (arrows) following treatment with heparanase or the KKDC peptide.
###end p 43
###begin p 44
Altogether, the results indicate that syndecan activation by soluble heparanase is sufficient to stimulate cell adhesion, function that clearly does not require heparanase enzymatic activity and is efficiently mimicked by the KKDC peptide.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sotnikov1">[28]</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-GingisVelitski2">[52]</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-GingisVelitski1">[39]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
###xml 658 664 658 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g007">Fig. 7</xref>
###xml 786 789 786 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">158</sup>
###xml 793 796 793 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">171</sup>
###xml 805 808 805 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">270</sup>
###xml 812 815 812 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sup>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 1186 1190 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Tkachenko2">[37]</xref>
We have previously noted that heparanase facilitates the adhesion, spreading, and migration of several cell types in a manner that appeared independent of its enzymatic activity [26]-[28], [52]. We have also noted that heparanase is internalized as a complex with syndecan family members [39], and induces Rac1 activation [26], yet the causal link between these observations was unclear. The results presented in this study merge these findings in a linear mode in which syndecan clustering by heparin binding domains of heparanase initiates signaling cascades that involve Rac1, Src, and the PKC pathways, resulting in enhanced cell adhesion and spreading (Fig. 7). Syndecan clustering and activation are likely mediated by the two functional heparin binding domains of heparanase (Lys158-Asp171 and Gln 270-Lys280) [29], which are mimicked by the KKDC peptide dimer. These results not only provide a molecular basis for non-enzymatic function of heparanase, but also suggest a novel mechanism by which syndecan molecules are activated. Thus, while syndecan clustering is thought to be mediated physiologically by ECM resident fibril fibronectin, or artificially engaged by antibodies [37], our results suggest that syndecans can also be activated by soluble ligands such as heparanase.
###end p 46
###begin title 47
A schematic diagram of HSPG activation by heparanase/KKDC.
###end title 47
###begin p 48
###xml 620 624 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser2">[42]</xref>
###xml 645 649 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Nadir1">[47]</xref>
###xml 659 663 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Okawa1">[60]</xref>
Clustering of syndecan family members, and possibly glypicans, by the KKDC dimer or the two heparin binding domains of heparanase facilitates cell-adhesion and cell-spreading (left). Enhanced cell adhesion and spreading is mediated by the recruitment and activation of PKCalpha, Rac1, and Src. In addition, heparanase is thought to interact with heparanase-binding cell surface protein/receptor, leading to HS-independent Akt activation. Similarly, p38 and Src activation by heparanase may also be mediated by this receptor, resulting in enhanced transcription of genes such as vascular endothelial growth factor (VEGF) [42], tissue factor (TF) [47], or Cox2 [60], and further contribute to cell adhesion, spreading and motility (right).
###end p 48
###begin p 49
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Verrecchio1">[53]</xref>
###xml 405 411 405 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g007">Fig. 7</xref>
###xml 650 658 650 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s005">Fig. S1A</xref>
###xml 836 840 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 875 881 875 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g007">Fig. 7</xref>
###xml 1108 1114 1108 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 1116 1120 1116 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-GingisVelitski1">[39]</xref>
###xml 1179 1183 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 1210 1216 1210 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 1415 1418 1415 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">270</sup>
###xml 1422 1425 1422 1425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sup>
###xml 1433 1436 1433 1436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">411</sup>
###xml 1440 1443 1440 1443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">432</sup>
###xml 1549 1553 1549 1553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 1619 1622 1619 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Cardin1">[9]</xref>
###xml 1969 1976 1969 1976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s006">Fig. S2</xref>
###xml 2203 2209 2203 2209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3</xref>
###xml 2245 2251 2245 2251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 2273 2280 2273 2280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g003">Fig. 3B</xref>
###xml 2404 2410 2404 2410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g004">Fig. 4</xref>
###xml 2661 2667 2661 2667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1</xref>
###xml 2880 2884 2880 2884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Saoncella1">[32]</xref>
###xml 2970 2974 2970 2974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser1">[26]</xref>
###xml 2976 2980 2976 2980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sotnikov1">[28]</xref>
###xml 3159 3165 3159 3165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g001">Fig. 1</xref>
###xml 2187 2191 <span type="species:ncbi:307630">Colo</span>
###xml 2257 2261 <span type="species:ncbi:307630">Colo</span>
###xml 2331 2336 <span type="species:ncbi:9606">human</span>
A key tool for deciphering this mode of heparanase function is provided by the KKDC peptide. A cysteine residue introduced at the peptide C-terminus mediates spontaneous peptide dimerization that can be further facilitated by enhanced oxygenation, a procedure shown to improve the interaction of peptides with heparin [53], yielding a two-headed molecule with intact heparin binding domains at both ends (Fig. 7). Indeed, the addition of ethandithiol (EDT) which binds covalently to the sulfate group of cysteine and prevents di-sulfide bridge formation between cysteine residues, markedly inhibited the interaction of the KKDC peptide with heparin (Fig. S1A) and its anti-heparanase activity (not shown). Thus, the peptide dimer and its two-headed heparin binding domains mimic the two functional heparin binding domains of heparanase [29], and enables syndecan clustering (Fig. 7). In fact, syndecan clusters elicited by the KKDC peptide appeared exceptionally large and failed to get internalized at the time points examined, while the heparanase-syndecan complex is rapidly and efficiently internalized (Fig. 2) [39]. The ability of the KKDC peptide to interact with heparin [29] and to cluster syndecans (Fig. 2) appears unique, since peptides derived from two additional domains in heparanase containing a Cardin-Weintraub consensus sequences and suspected to mediate its interaction with heparan sulfate (Gln270-Lys280 and Lys411-Arg432) exhibited only a very weak interaction with heparin and failed to inhibit heparanase enzymatic activity [29]. Thus, the mere presence of Cardin-Weintraub consensus sequences [9] appears not sufficient to ensure bioactive peptide, further highlighting the unique feature of the KKDC peptide. Moreover, a peptide derived from the C-terminal heparin-binding domain of fibronectin failed to facilitate the adhesion of ARH-77 leukemia-derived F cells, compared with a significant pro-adhesive effect exerted by the KKDC peptide (Fig. S2 and data not shown). Notably, cells treated with the KKDC peptide appeared better spread and formed more focal contacts compared with cells treated with heparanase. This was evident by the morphology of C6 and Colo 320 cells (Fig. 3), paxillin staining of U87 glioma (Fig. 2) and Colo 320 cells (Fig. 3B), and phalloidin and vinculin staining of CHO and human skin fibroblasts plated on the 110 kDa fibronectin-like substrate (Fig. 4), indicating that syndecan clustering by the KKDC peptide is translated biochemically to cellular response. In contrast, heparanase appeared more efficient in stimulating the adhesion of floating ARH-77 leukemia cells compared with the KKDC peptide (Fig. 1). This result indicates that syndecan activation alone by the KKDC peptide may not be sufficient for efficient cell adhesion, and that cooperation with additional adhesion molecules such as integrins is required [32]. Integrin activation was noted upon heparanase over expression or exogenous addition [26], [28]. This activation does not seem to involve enzymatic aspects since mutated, inactive heparanase (DM) was as potent as wild type heparanase in facilitating ARH-77 F cell adhesion (Fig. 1). The molecular mechanism underlying integrin activation by heparanase awaits detailed characterization.
###end p 49
###begin p 50
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Couchman1">[31]</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Woods1">[34]</xref>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Simons1">[54]</xref>
###xml 366 372 366 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Beauvais1">[30]</xref>
###xml 838 842 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Couchman1">[31]</xref>
###xml 950 954 950 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Beauvais1">[30]</xref>
###xml 956 960 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Tkachenko1">[33]</xref>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Lin1">[55]</xref>
###xml 1411 1417 1411 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002319-g002">Fig. 2</xref>
The prime syndecan candidate for mediating the effect of heparanase/KKDC on cell adhesion is syndecan-4 since this molecule is ubiquitously expressed and is the only syndecan that appears to reside at, and exhibit a functional role in the assembly of focal adhesions [31], [34], [54]. The KKDC peptide, however, clustered efficiently both syndecan-1 and syndecan-4 (Fig. 2) and possibly additional syndecan family members, raising the possibility that enhanced cell adhesion and spreading is not solely mediated by syndecan-4. Indeed, essentially all syndecan family members are implicated in cell adhesion. For example, over expression of syndecan-1 in syndecan deficient Raji lymphoblastoid or COS-7 cells stimulated cell spreading [30]. Similarly, syndecan-2 was noted to promote focal adhesion formation in Lewis-lung carcinoma cells [31], and syndecan-2 and syndecan-3 induce filopodia formation in COS-1, CHO-K1, Swiss 3T3, and dendritic cells [30], [33], [55]. It is therefore likely that heparanase/KKDC induce the clustering of more than one syndecan family member and, possibly, also of glypicans, leading to enhanced cell adhesion and spreading. This possibility is further supported by the localization of syndecans following the addition of heparanase or the KKDC peptide. Clusters of syndecan-1 and syndecan-4 were similarly distributed on the cell surface following addition of the KKDC peptide (Fig. 2) in a pattern that does not coincide with focal complexes. Rapid internalization of heparanase-syndecan complexes following heparanase addition clearly implies that enhanced cell adhesion does not require localization of syndecans at focal adhesions, but rather involves syndecan activation.
###end p 50
###begin p 51
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Beauvais1">[30]</xref>
###xml 463 467 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Ilan1">[22]</xref>
###xml 469 473 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky5">[25]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Sanderson2">[56]</xref>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Yang1">[57]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Yang3">[59]</xref>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Ilan1">[22]</xref>
###xml 832 836 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Vlodavsky5">[25]</xref>
###xml 780 788 <span type="species:ncbi:9606">patients</span>
Syndecan activation by soluble ligands such as heparanase may also have important clinical implications. Over expression of syndecan-1 has been observed in pancreatic, gastric and breast carcinomas, correlating with increased tumor aggressiveness and poor clinical prognosis, while syndecan-2 is often over expressed in colon carcinoma, and syndecan-4 is up-regulated in hepatocellular carcinoma [30], coinciding with heparanase up-regulation in these carcinomas [22], [25]. Syndecan-1 is particularly abundant in multiple myeloma [56], where an emerging role for heparanase has recently been shown [57]-[59]. Thus, elevated levels of heparanase may activate syndecan family members and promote tumor metastasis and angiogenesis, resulting in poor prognosis often associated with patients exhibiting high levels of heparanase [22], [25].
###end p 51
###begin p 52
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-LevyAdam1">[29]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser3">[44]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser3">[44]</xref>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002319-Zetser3">[44]</xref>
###xml 727 735 727 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002319.s005">Fig. S1B</xref>
Taken together, the results clearly highlight heparanase as a multi functional protein, exhibiting enzymatic activity-dependent and -independent functions. Better understanding of the basic biology of this protein will contribute to the development of efficient heparanase inhibitors directed, for example, against the heparin binding domains of heparanase [29], [44]. Monoclonal antibodies or small molecules directed against this domain will not only inhibit heparanase enzymatic activity [44], but will also suppress syndecans activation, resulting in a more efficient neutralization of heparanase functions. On the other hand, the anti-cancer efficacy of the KKDC peptide which inhibits heparanase enzymatic activity [44] (Fig. S1B) is questionable taking into account its pro-adhesive properties.
###end p 52
###begin title 53
Supporting Information
###end title 53
###begin p 54
###xml 23 26 <span type="species:ncbi:10116">Rat</span>
Time lapse microscopy. Rat C6 glioma cells (2x104) were plated in a 6-well plate in complete growth medium, followed by 20 hours incubation in serum-free medium. Cells were then incubated with control scrambled peptide. Six fields in each well were randomly selected, and were examined every 10 min for 10 hours by the time lapse system. Representative time lapse movie is shown.
###end p 54
###begin p 55
(6.15 MB AVI)
###end p 55
###begin p 56
Click here for additional data file.
###end p 56
###begin p 57
###xml 23 26 <span type="species:ncbi:10116">Rat</span>
Time lapse microscopy. Rat C6 glioma cells (2x104) were plated in a 6-well plate in complete growth medium, followed by 20 hours incubation in serum-free medium. Cells were then incubated with heparanase (1 microg/ml); Six fields in each well were randomly selected, and were examined every 10 min for 10 hours by the time lapse system. Representative time lapse movie is shown.
###end p 57
###begin p 58
(7.14 MB AVI)
###end p 58
###begin p 59
Click here for additional data file.
###end p 59
###begin p 60
###xml 23 26 <span type="species:ncbi:10116">Rat</span>
Time lapse microscopy. Rat C6 glioma cells (2x104) were plated in a 6-well plate in complete growth medium, followed by 20 hours incubation in serum-free medium. Cells were then incubated with the KKDC peptide; Six fields in each well were randomly selected, and were examined every 10 min for 10 hours by the time lapse system. Representative time lapse movie is shown.
###end p 60
###begin p 61
(6.99 MB AVI)
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin p 63
###xml 23 26 <span type="species:ncbi:10116">Rat</span>
Time lapse microscopy. Rat C6 glioma cells (2x104) were plated in a 6-well plate in complete growth medium, followed by 20 hours incubation in serum-free medium. Cells were then incubated with the KKDC peptide with heparin (10\microg/ml); Six fields in each well were randomly selected, and were examined every 10 min for 10 hours by the time lapse system. Representative time lapse movie is shown.
###end p 63
###begin p 64
(6.15 MB AVI)
###end p 64
###begin p 65
Click here for additional data file.
###end p 65
###begin p 66
KKDC peptide dimerization significantly improves heparin binding and anti-heparanase properties. A. Heparin binding. KKDC peptide was synthesized in the absence (KKDC) or presence of ethandithiol (EDT), which binds covalently to the sulfate group of cysteine and prevents di-sulfide bridge formation between cysteine residues. Peptides (50 microM) were incubated (2 hours, 4degreesC) with heparin-Sepharose beads in PBS, washed with PBS supplemented with NaCl to a final concentration of 0.35 M, followed by one wash with PBS. Dye-free sample buffer was added and the beads were boiled for 5 minuntes, centrifuged and the supernatants were loaded on Tris-Tricine gel. Subsequently, gels were stained with Coomassie blue to visualize bound peptides (arrow). B. Heparanase enzymatic activity. B16 melanoma cells (2x106) were resuspended in RPMI medium and incubated (18 hours, 37degreesC) with 35S-labeled ECM in the absence (filled rectangle) or presence of control scrambled peptide dimer (green rectangle; 50 microM), KKDC peptide undergoing spontaneous dimerization (filled triangle; 50 microM), KKDC peptide following enhanced dimerization (blue rectangle; 50 microM), or heparin (filled circle; 15 microg/ml). The incubation medium (1 ml) containing sulfate labeled degradation fragments was subjected to gel filtration on a Sepharose CL-6B column. Fractions (0.2 ml) were eluted with PBS and their radioactivity counted in a beta-scintillation counter. Degradation fragments of HS side chains are eluted at 0.5<Kav<0.8 (peak II, fractions 15-40) and represent heparanase degradation products.
###end p 66
###begin p 67
(0.61 MB TIF)
###end p 67
###begin p 68
Click here for additional data file.
###end p 68
###begin p 69
Leukemia-derived ARH-77 cells that were selected to grow in suspension (F cells), were plated on gelatin coated plates for 30 minutes in the presence of the KKDC (50 microM), Hep II (100 microM), or control (Scr) peptide (50 microM). Plates were then gently washed and cell adhesion was visualized by light microscopy.
###end p 69
###begin p 70
(0.31 MB TIF)
###end p 70
###begin p 71
Click here for additional data file.
###end p 71
###begin title 72
References
###end title 72
###begin article-title 73
Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics.
###end article-title 73
###begin article-title 74
Proteoglycans: structures and interactions.
###end article-title 74
###begin article-title 75
Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes.
###end article-title 75
###begin article-title 76
Roles of heparan-sulphate glycosaminoglycans in cancer.
###end article-title 76
###begin article-title 77
Functions of cell surface heparan sulfate proteoglycans.
###end article-title 77
###begin article-title 78
Heparan sulphate proteoglycans: the sweet side of development.
###end article-title 78
###begin article-title 79
Supramolecular assembly of basement membranes.
###end article-title 79
###begin article-title 80
Heparin-protein interactions.
###end article-title 80
###begin article-title 81
Molecular modeling of protein-glycosaminoglycan interactions.
###end article-title 81
###begin article-title 82
Heparan sulfate proteoglycan as a plasma membrane carrier.
###end article-title 82
###begin article-title 83
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix.
###end article-title 83
###begin article-title 84
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.
###end article-title 84
###begin article-title 85
A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane.
###end article-title 85
###begin article-title 86
Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.
###end article-title 86
###begin article-title 87
Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?
###end article-title 87
###begin article-title 88
Matrix metalloproteinases and the regulation of tissue remodelling.
###end article-title 88
###begin article-title 89
ECM and cell surface proteolysis: regulating cellular ecology.
###end article-title 89
###begin article-title 90
Heparanase: a target for drug discovery in cancer and inflammation.
###end article-title 90
###begin article-title 91
Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells.
###end article-title 91
###begin article-title 92
###xml 85 90 <span type="species:ncbi:10090">Mouse</span>
Heparan sulfate degradation: relation to tumor invasion and metastatic properties of Mouse B 16 Melanoma sublines.
###end article-title 92
###begin article-title 93
Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis.
###end article-title 93
###begin article-title 94
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
###end article-title 94
###begin article-title 95
Development of heparanase inhibitors for anti-cancer therapy.
###end article-title 95
###begin article-title 96
Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis.
###end article-title 96
###begin article-title 97
The impact of heparanese and heparin on cancer metastasis and angiogenesis.
###end article-title 97
###begin article-title 98
###xml 57 62 <span type="species:ncbi:9606">human</span>
Heparanase affects adhesive and tumorigenic potential of human glioma cells.
###end article-title 98
###begin article-title 99
Heparanase mediates cell adhesion independent of its enzymatic activity.
###end article-title 99
###begin article-title 100
Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts.
###end article-title 100
###begin article-title 101
Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
###end article-title 101
###begin article-title 102
Syndecans in tumor cell adhesion and signaling.
###end article-title 102
###begin article-title 103
Syndecans: proteoglycan regulators of cell-surface microdomains?
###end article-title 103
###begin article-title 104
Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.
###end article-title 104
###begin article-title 105
Syndecans: new kids on the signaling block.
###end article-title 105
###begin article-title 106
Syndecan-4 and focal adhesion function.
###end article-title 106
###begin article-title 107
Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix.
###end article-title 107
###begin article-title 108
PKCbeta-dependent activation of RhoA by syndecan-4 during focal adhesion formation.
###end article-title 108
###begin article-title 109
Syndecan-4 clustering induces cell migration in a PDZ-dependent manner.
###end article-title 109
###begin article-title 110
A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation.
###end article-title 110
###begin article-title 111
Heparanase Uptake Is Mediated by Cell Membrane Heparan Sulfate Proteoglycans.
###end article-title 111
###begin article-title 112
The generation and regulation of functional diversity of malignant plasma cells.
###end article-title 112
###begin article-title 113
Identification of active-site residues of the pro-metastatic endoglycosidase heparanase.
###end article-title 113
###begin article-title 114
Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.
###end article-title 114
###begin article-title 115
Characterization of mechanisms involved in secretion of active heparanase.
###end article-title 115
###begin article-title 116
Processing and activation of latent heparanase occurs in lysosomes.
###end article-title 116
###begin article-title 117
Heterodimer formation is essential for heparanase enzymatic activity.
###end article-title 117
###begin article-title 118
Cellular Uptake of Mammalian Heparanase Precursor Involves Low Density Lipoprotein Receptor-related Proteins, Mannose 6-Phosphate Receptors, and Heparan Sulfate Proteoglycans.
###end article-title 118
###begin article-title 119
Heparanase induces tissue factor expression in vascular endothelial and cancer cells.
###end article-title 119
###begin article-title 120
Molecular biology of fibronectin.
###end article-title 120
###begin article-title 121
Localization of the major heparin-binding site in fibronectin.
###end article-title 121
###begin article-title 122
Rho and Rac take center stage.
###end article-title 122
###begin article-title 123
Integrins regulate Rac targeting by internalization of membrane domains.
###end article-title 123
###begin article-title 124
Heparanase induces endothelial cell migration via protein kinase B/Akt activation.
###end article-title 124
###begin article-title 125
Design of peptides with high affinities for heparin and endothelial cell proteoglycans.
###end article-title 125
###begin article-title 126
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</bold>
Syndecan-4-mediated signalling.
###end article-title 126
###begin article-title 127
Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway.
###end article-title 127
###begin article-title 128
Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies.
###end article-title 128
###begin article-title 129
Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
###end article-title 129
###begin article-title 130
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
###end article-title 130
###begin article-title 131
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
###end article-title 131
###begin article-title 132
Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2.
###end article-title 132
###begin p 133
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 133
###begin p 134
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the Israel Science Foundation (grant 549/06); National Cancer Institute, NIH (grant RO1-CA106456); the Israel Cancer Research Fund; and the Rappaport Family Institute Fund.
###end p 134

